Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM

Newly Diagnosed Multiple Myeloma Clinical Trial

Official title:

Isatuximab in Combination With Lenalidomide-Dexamethasone Compared to Lenalidomide-Dexamethasone in Elderly Patients (Aged ≥70 Years) With Newly Diagnosed Myeloma: a Randomized Phase II Study (SGZ-2019-12650)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04891809
• Other study ID #: AGMT_MM-4
• Status: Recruiting
• Phase: Phase 2
• Start date: October 20, 2021
• Est. completion date: December 2028

Study information

• Verified date: November 2023
• Source: Arbeitsgemeinschaft medikamentoese Tumortherapie
• Contact: Daniela Wolkersdorfer
• Phone: +43 662640
• Email: d.wolkersdorfer[@]agmt.at
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

As optimal tolerance is the key for developing new treatments for the very elderly population, the aim of the study is to compare the efficacy and tolerance of isatuximab in combination with lenalidomide+dexamethasone (Rd) versus Rd only in very elderly patients aged 70 years or older. ln sum, a clear and clinically highly relevant benefit is expected with the isatuximab-based triple combination compared to the standard Rd doublet.

Description:

The treatment goals in elderly patients with multiple myeloma (MM) are similar to those in younger patients: rapid and long-lasting symptom control, deep response and durable remissions as well as increased survival are at the forefront, similar to therapy goals in younger patients. Elderly patients frequently present with comorbidities, reduced treatment tolerance and greater frequency of treatment discontinuations. Hence, treatment needs to be adapted to the specific needs of this patient population. ln the recent decade lenalidomide-based therapies have been established as effective treatment modalities in elderly patients. In elderly patients lenalidomide + dexamethasone (Rd) is one of the most frequently used treatment regimens, which is effective and well tolerated. MM is a high unmet medical need and as a result, several agents are currently under clinical investigation in MM. Monoclonal antibodies (mAb) are one of the most promising groups of drugs in development in the treatment of MM with several of them demonstrating activity in this disease. lsatuximab is a highly effective monoclonal antibody with an excellent activity and tolerance profile, active as single agent therapy in patients with multiple prior lines of treatment. Presently several trials with isatuximab-lenalidomide containing treatment regimens are ongoing. The expected benefits of adding isatuximab to Rd over Rd alone in very elderly patients seem to outweigh possible risks by far. A greater depth of response is anticipated including greater number of MRD (minimal residual disease) negative patients, higher response rates, and longer progression free survival. Risk conferred with the addition of isatuximab are mainly restricted to a roughly 40% rate of infusion reactions, which usually are seen at the first infusion only. ln addition, there is an increased risk for grade 4 leukopenia, grade 2 and 3 thrombocytopenia, and grade 3 infection and fatigue.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 198
• Est. completion date: December 2028
• Est. primary completion date: December 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 70 Years and older

Eligibility

Inclusion Criteria:

• Age = 70 years
• Able to provide written informed consent in accordance with federal, local, and institutional guidelines
• Patients must have newly diagnosed, symptomatic multiple myeloma with evidence of measurable disease (assessed within 21 days prior to randomization)
• Serum M protein =0.5 g/dL measured using serum protein immunoelectrophoresis and/or
• Urine M protein =200 mg/24 hours measured using urine protein immunoelectrophoresis and/or
• In subjects without detectable serum or urine M-protein, serum-free light chain (SFLC) =100 mg/L (involved light chain) and an abnormal FLC ratio
• No prior treatment for multiple myeloma
• Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-2
• Patients at cardiac risk (NYHA >ll) or pre-existing coronary heart disease, or any other clinically relevant cardiac complication) should be scheduled for a baseline ECHO and can only be included if the LVEF is >40%
• Adequate organ and bone marrow function within the 21 days prior to randomization

defined by:

• Bilirubin < 2 times the upper limit of normal (ULN), Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 times the ULN
• absolute neutrophil count (ANC) = 750/mm3 (growth factor support for max 3 days allowed to achieve this value)
• Hemoglobin >8.0 g/dL (Use of erythropoietic stimulating factors and red blood cell [RBC] transfusion per institutional guidelines is allowed, however the most recent RBC transfusion may not have been done within 7 days prior to obtaining screening hemoglobin.)
• Platelet count >50,000/mm3
• Calculated or measured creatinine clearance (CrCl) of =30 mL/min; Calculation should be based on the MDRD formula (age, gender, black/non- black, weight, height)

Exclusion Criteria:

• ECOG status >2
• Patients unlikely to tolerate Rd
• Waldenström macroglobulinemia
• POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)
• Plasma cell leukemia (> 2.0 x 10^9/L circulating plasma cells by standard differential)
• Myelodysplastic syndrome
• Smoldering Myeloma and MGUS
• Second malignancy within the past 5 years except:
• Adequately treated basal cell or squamous cell skin cancer
• Carcinoma in situ of the cervix
• Prostate cancer = Gleason score 6 with stable prostate-specific antigen (PSA over 12 months)
• Ductal breast carcinoma in situ with full surgical resection (i.e., negative margins)
• Treated medullary or papillary thyroid cancer
• History of or current amyloidosis
• Glucocorticoid therapy within the 14 days prior to randomization that exceeds an accumulated dose of 160 mg dexamethasone or 1000 mg prednisone
• Extended field radio therapy (more than 3 fields) within the 21 days prior to randomization
• Contraindication to isatuximab, dexamethasone, lenalidomide or any of the required concomitant drugs or supportive treatments, including hypersensitivity to antiviral drugs
• Active congestive heart failure (New York Heart Association [NYHA] Class III or IV), symptomatic ischemia, conduction abnormalities uncontrolled by conventional intervention, acute diffuse infiltrative pulmonary disease, pericardial disease, or myocardial infarction within 4 months prior to enrolment
• Active infection within the 14 days prior to randomization requiring systemic antibiotics and/or antiviral therapy
• Uncontrolled hypertension or uncontrolled diabetes despite medication
• Significant neuropathy (Grade 2 with pain or Grade 3 or higher) within the 14 days prior to randomization
• Known cirrhosis
• Known human immunodeficiency virus (HIV) seropositivity or active hepatitis C or hepatitis B infection (subjects with past hepatitis B virus [HBV] infection or resolved HBV infection defined as having a negative HBsAg test and a positive antibody to hepatitis B core antigen [anti HBc] antibody test are eligible; subjects positive for hepatitis C virus [HCV] antibody are eligible only if polymerase chain reaction [PCR] is negative for HCV RNA.)
• Participation in another interventional study within the 28 days prior to randomization
• Major surgery (except kyphoplasty) within the 28 days prior to randomization
• Any other clinically significant medical disease or social condition that, in the Investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent, be compliant with study procedures, or provide accurate information.

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell
• Newly Diagnosed Multiple Myeloma

Intervention

Drug:
• Isatuximab-Irfc 20 MG/ML [Sarclisa]
Induction: 10mg/kg on day 1,8,15,22 in cycle 1, subsequently on day 1, 15; every 28 days (q28 days) Maintenance: 10mg/kg, day1, q28 days until progression or intolerance but for a maximum of 24 cycles from start of maintenance
• Lenalidomide
Induction: 25mg*, day 1-21, every 28 days (q28 days); Maintenance: 5-10mg, day 1-21, q28 days (according to individual tolerance) until progression or intolerance but for a maximum of 24 cycles from start of maintenance *) for patients with moderate renal impairment (30= GFR (MDRD formula) < 50 mL/min) starting dose is 10 mg
• Dexamethasone Oral
Induction: Patients aged <75 years: 40mg, once weekly; Patients aged =75 years: 20mg, once weekly

Locations

Country	Name	City	State
Austria	Med.Univ.Graz, Univ.-Klinikum f. Innere Medizin, Klin. Abt. f. Haematologie	Graz
Austria	Univ.-Klinik für Innere Medizin V Innsbruck, Abteilung für Hämatologie und Onkologie	Innsbruck	Tirol
Austria	Klinik Klagenfurt am Wörthersee Abteilung für Innere Medizin und Hämatologie und internistische Onkologie	Klagenfurt
Austria	Bezirkskrankenhaus Kufstein, Innere Medizin, Interne II u. onkologische Tagesklinik	Kufstein
Austria	LKH Hochsteiermark - Leoben, Abt. f. Innere Medizin, Haemato-Onkologie	Leoben
Austria	JKU Linz, Univ.-Klinik f. Hämatologie und Internistische Onkologie, MC III.	Linz
Austria	Univ.Klinikum Krems, Klin. Abt. f. Innere Medizin 2	Mitterweng
Austria	LKH Feldkirch, Innere Medizin II, Interne E: Hämatologie und Onkologie	Rankweil
Austria	PMU Salzburg: Universitätsklinik für Innere Medizin III	Salzburg
Austria	Univ.-Klinikum St. Pölten, Innere Medizin 1	St.Pölten
Austria	AKH Meduni Wien Universitätsklinik für Innere Medizin I: Klinische Abteilung für Hämatologie und Hämostaseologie	Vienna
Austria	Klinik Hietzing, 5. Medizinische Abteilung	Vienna
Austria	Klinik Ottakring, 1.Med.Abt., Zentrum f. Onkologie, Haematologie und Palliativmedizin	Vienna
Austria	Krankenhaus d. Barmh. Schwestern Wien, 1. Med. Abteilung, Onkologie und Hämatologie	Vienna
Austria	Hanusch Krankenhaus der Österreichischen Gesundheitskasse, 3. Med. Abteilung	Wien
Austria	Krankenhaus Zams, Innere Medizin, Internistische Onkologie-Haematologie	Zams
Greece	General Hospital of Athens "Alexandra, Plasma Cell Dyscrasias Unit	Athens
Greece	General Hospital of Athens "Evangelismos", Hematology Clinic	Athens
Greece	Anticancer Hospital of Thessaloniki "Theageneio", Hematology	Thessaloníki
Serbia	University Clinical Center of Serbia, Clinic for Hematology	Belgrade
Serbia	University Clinical Center Kragujevac, Clinic for Hematology	Kragujevac
Serbia	University Clinical Center Nis, Clinic for Hematology	Niš
Serbia	Clinical center of Vojvodina, Clinic for Hematology	Novi Sad

Sponsors (6)

Lead Sponsor	Collaborator
Arbeitsgemeinschaft medikamentoese Tumortherapie	Assign Data Management and Biostatistics GmbH, Medical University of Vienna, Sanofi, University of Navarra, WiSP GmbH

Countries where clinical trial is conducted

Austria,  Greece,  Serbia, 

References & Publications (1)

Facon T, Dimopoulos MA, Meuleman N, Belch A, Mohty M, Chen WM, Kim K, Zamagni E, Rodriguez-Otero P, Renwick W, Rose C, Tempescul A, Boyle E, Manier S, Attal M, Moreau P, Macro M, Leleu X, Lorraine Chretien M, Ludwig H, Guo S, Sturniolo M, Tinel A, Silvia Monzini M, Costa B, Houck V, Hulin C, Yves Mary J. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia. 2020 Jan;34(1):224-233. doi: 10.1038/s41375-019-0539-0. Epub 2019 Aug 19. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of patients with MRD (minimal residual disease) negativity (defined by NGF [next generation flow] at 10^-5) after end of induction treatment in the two arms.	To demonstrate the benefit of isatuximab in combination with lenalidomide and low-dose dexamethasone followed by isatuximab and lenalidomide maintenance therapy in changing the proportion of patients with MRD negativity as compared to lenalidomide and low-dose dexamethasone followed by lenalidomide maintenance treatment in patients with newly diagnosed multiple myeloma (NDMM).	After 8 months of induction treatment (8 cycles, each cyle is 28 days)
Secondary	Percentage of patients with response to study treatment	Effect of treatment on Overall Response Rate (ORR) including patients with Partial Response (PR), Very Good Partial Response (VGPR) and Complete Response (CR) as per International Myeloma Working Group (IMWG) criteria in each arm.	After 32 months (8 months of induction treatment and a maximum of 24 months of maintenance treatment)
Secondary	Progression-free Survival	Effectiveness of treatments on Progression-free survival (PFS)	After 44 months (8 months of induction treatment and a maximum of 24 months of maintenance treatment and a minimum of 12 months of follow-up)
Secondary	Overall Survival	Effectiveness of treatments on Overall Survival (OS)	After 44 months (8 months of induction treatment and a maximum of 24 months of maintenance treatment and a minimum of 12 months of follow-up)
Secondary	Effectiveness of treatments on MRD negativity	To evaluate the proportion of patients with MRD negativity (defined by NGF [next generation flow] at 10^-5) after 12 months (13 cycles) of maintenance treatment.	After 20 months (8 months of induction treatment and 12 months of maintenance treatemnent)
Secondary	Effectiveness of treatments on preventing progressive disease	To evaluate the Time to Progression (TTP) in each arm.	After 44 months (8 months of induction treatment and a maximum of 24 months of maintenance treatment and a minimum of 12 months of follow-up)
Secondary	Progression-free Survival in different high-risk cytogenetic populations	Effectiveness of treatment on PFS in high risk cytogenetic populations defined as patients carrying a) del(17p), t(4;14), t(14;16) in each arm and b) the same aberrations plus amp1q21.	After 44 months (8 months of induction treatment and a maximum of 24 months of maintenance treatment and a minimum of 12 months of follow-up)
Secondary	Duration of response	Length of time between response and progression or death.	After 44 months (8 months of induction treatment and a maximum of 24 months of maintenance treatment and a minimum of 12 months of follow-up)
Secondary	Incidence of treatment-emergent adverse events (Safety and tolerability)	Number of participants with treatment-emergent adverse events as assessed by NCI-CTCAE Version 5.0.	After 32 months (8 months of induction treatment and a maximum of 24 months of maintenance treatment)
Secondary	Changes in quality of life (QoL) using general questionnaire European Organization for Research and Treatment of Cancer (EORTC) Quality of life questionnaire (QLQ) Core 30 (C 30) (EORTC-QLQ-C30)	Changes in quality of life will be analyzed by using the cancer patient-specific questionnaire EORTC-QLQ-C30.	After 32 months (8 months of induction treatment and a maximum of 24 months of maintenance treatment)
Secondary	Changes of general health status using questionnaire EQ (EuroQol) 5 dimension (5D) 5 level (5L) (EQ-5D-5L)	Changes in general health status will be analyzed by using the questionnaires EQ-5D-5L. QoL.	After 32 months (8 months of induction treatment and a maximum of 24 months of maintenance treatment)
Secondary	Changes in quality of life (QoL) using multiple myeloma specific questionnaire EORTC-QLQ Myeloma (MY) 20 (EORTC-QLQ-MY20)	Changes in quality of life will be analyzed by using the multiple myeloma-specific questionnaire EORTC-QLQ-MY20.	After 32 months (8 months of induction treatment and a maximum of 24 months of maintenance treatment)
Secondary	Progression-free survival after second line therapy	Influence of potential second line therapy on Progression-free Survival	After end of study treatment until 12 months of follow up as a minimum (until LPLV)

External Links

•   Sponsor